A review on characteristics and analytical methods of atovaquone – a potent antimalarial agent
Keywords:Malaria, Antimalarial drugs, Atovaquone, Analytical methods, HPLC
Drugs used in the treatment of malaria that is caused by various plasmosium species i.e. P. falciparum, P. vivax are most irresistible disease throughout the world. The different medications are utilized in the treatment of malaria incorporated the Aryl aminoalcohol mixes: Quinine, Quinidine, Chloroquine, Mefloquine; Antifolate compound: Pyrimethamine, Proguanil, Chlorproguanil, Trimethoprim and Atovaquone. Atovaquone is most effective drug utilized in the treatment of malaria. It must be given in single or in mixture with different antimalarials. An enormous number of methodologies including High Performance Liquid chromatography (HPLC), UV–Visible spectroscopy and Liquid Chromatography-Mass Spectroscopy (LC-MS) are utilized for the determination of atovaquone. Various analytical methods are used for the analysis of pharmaceutical products and these methods were validated according to ICH guidelines (Q1A R2). Thus, this technique can be safely used for the standard quality control analysis of atovaquone.
Bruce-Chwatt LJ. Malaria and its control: present situation and future prospects. Annu Rev Public Health 8, 75-110. (1987).
Sahu M, Tediosi F, Noor AM, Aponte JJ, Fink G. Health systems and global progress towards malaria elimination, 2000-2016. Malar. J.,19, 1-2 (2020).
World Health Organization. World Malaria Report 2015 - Summary, 2015.
Tangena JA, Hendriks CMJ, Devine M, Tammaro M, Trett AE, Williams I, DePina AJ, Sisay A, Herizo R, Kafy HT, Chizema E, Were A, Rozier J, Coleman M, Moyes CL. Indoor residual spraying for malaria control in sub-Saharan Africa 1997 to 2017: an adjusted retrospective analysis. Malar. J. 19, 150. (2020).
Wellems TE, Plowe CV. Chloroquine-resistant malaria. J. Infect. Dis. 184, 770-6. (2001).
Le Bras J, Durand R. The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam. Clin. Pharmacol., 17, 147-153 (2003).
Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LMB, Bir Singh Sidhu A, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell, 6, 861-871 (2000).
Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2, 209-18. (2002).
Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 5, e128. (2008).
Ringwald P. Current antimalarial drugs: Resistance and new strategies. Bull. Acad. Natl. Med., 191, 1273-1284 (2007).
Chishimba S, Kobayashi T, Mulenga M, Phiri M, Mharakurwa S, Thuma P, Moss WJ. The impact of insecticide-treated nets on acquired humoral immunity to plasmodium falciparum. Am. J. Trop. Med. Hyg.,83, 361 (2010).
Pouniotis DS, Proudfoot O, Minigo G, Hanley JL, Plebanski M. Malaria parasite interactions with the human host. J Postgrad Med 50, 30-4. (2004).
Newbold CI. Antigenic variation in Plasmodium falciparum: mechanisms and consequences. Curr. Opin. Microbiol. 2, 420-5. (1999).
Sinnis P. The malaria sporozoite's journey into the liver. Infect Agents Dis. 5, 182-189 (1996)
https://www.yourgenome.org/facts/what-is-malaria . Accessed 15 june, 2020. image credit: Genome Research Limited.
Tripathi K. Essential of Medical Pharmacology (7th Edition). (2013).
Dutta GP. New antimalarial drug discovery in India and future strategy for malaria control. Proc. Indian Natl. Sci. Acad., 1, 82 (2016).
Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. oncotarget., 8, 38022 (2017).
Chattopadhyay R, Mahajan B, Kumar S. Assessment of safety of the major antimalarial drugs. Expert opinion on drug safety., 6, 505-521 2007.
Dhanawat M, Das N, Nagarwal R, Shrivastava S. Antimalarial Drug Development: Past to Present Scenario. Mini-Reviews Med. Chem., 9, 1447-1469 (2009).
Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4’-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80). Biochem. Pharmacol., 43, 1545-1553 (1992).
Winter RW, Kelly JX, Smilkstein MJ, Dodean R, Hinrichs D, Riscoe MK. Antimalarial quinolones: Synthesis, potency, and mechanistic studies. Exp. Parasitol., 118, 487-497 (2008).
Paul MA, McCarthy AE, Gibson N, Kenny G, Cook T, Gray G. The impact of Malarone® and primaquine on psychomotor performance. Aviat. Sp. Environ. Med., 74, 738-745 (2003).
Tripathi AS, Sheikh I, Dewani AP, Shelke PG, Bakal RL, Chandewar A V., Mazumder PM. Development And Validation Of Rp-Hplc Method For Sildenafil Citrate In Rat Plasma-Application To Pharmacokinetic Studies. Saudi Pharm. J., 21, 371-321 (2013).
GlaxoSmithKline (June 2015). "Mepron". Drugs.com. Retrieved 22 (2016).
Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii Pneumonia in the Non–HIV-Infected Population. Ann. Pharmacother., 50, 673-679 (2016).
Ling J, Baird JK, Fryauff DJ, Sismadi P, Bangs MJ, Lacy M, Barcus MJ, Gramzinski R, Maguire JD, Kumusumangsih M, Miller GB, Jones TR, Chulay JD, Hoffman SL. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin. Infect. Dis., 326, 825-833 (2002).
Kessl JJ, Lange BB, Merbitz-Zahradnik T, Zwicker K, Hill P, Meunier B, Pálsdóttir H, Hunte C, Meshnick S, Trumpower BL. Molecular basis for atovaquone binding to the cytochrome bc1 complex. J. Biol. Chem., 278, 31312-31318 (2003).
Hudson AT. Atovaquone - a novel broad-spectrum anti-infective drug. Parasitol. Today, 9, 66-68 (1993).
Winter R, Kelly JX, Smilkstein MJ, Hinrichs D, Koop DR, Riscoe MK. Optimization of endochin-like quinolones for antimalarial activity. Exp. Parasitol., 127, 545-551(2011).
Biagini GA, Viriyavejakul P, O’Neill PM, Bray PG, Ward SA. Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria. Antimicrob. Agents Chemother., 50, 1841-1851 (2006).
Nixon GL, Moss DM, Shone AE, Lalloo DG, Fisher N, O’neill PM, Ward SA, Biagini GA. Antimalarial pharmacology and therapeutics of atovaquone. journal of Antimicrobial Chemotherapy., 68, 977-985 (2013).
Ryley JF. The mode of action of proguanil and related antimalarial drugs. Br. J. Pharmacol. Chemother., 8, 424 (1953).
Brown W, Marques M. The United States Pharmacopeia/National Formulary. 319 (2013).
Vaidya AB, Mather MW. Atovaquone resistance in malaria parasites. Drug Resist. Updat., 3, 283-287 (2000).
Haile LG, Flaherty JF. Atovaquone: A review. Ann. Pharmacother., 27, 977-985 (1993).
McKeage K, Scott LJ, Borrmann S, De Vries PJ, Hutchinson DBA, Looareesuwan S, Nosten F, Price R, Shanks GD. Atovaquone/proguanil: A review of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs., 63, 597-623 (2003).
Varsha HC, Ajit AP, Kulkarni CG and Burade KB. Development and evaluation of spectrophotometric method for the estimation of Atovaquone in pharmaceutical dosage form. International Journal of Pharmaceutical Sciences and Research., 4, 3965-3970 (2013).
Srujani C, Satish V, P Adam K. UV-Spectrophotometric Method for the Estimation of Atovaquone in Bulk and Pharmaceutical Dosage form Using Hydrotropic Solubilization Technique. Semantic scholar., (2015).
Patel KN, Patel JK, Patel MP, Rajput GC. A validated method for development of atovaquone as API and tablet dosage forms by UV spectroscopy. Pharmaceutical Methods. 1, 61-64 (2010).
Rao AL, Prasanthi T, Thunnisa F. Development and Validation for Simultaneous Estimation of Proguanil and Atovaquone by using RP-HPLC. Int. J. Anal. Tech., 3, 1–10 (2018).
Naazneen S, Sridevi A. stability indicating rp-hplc method for the simultaneous estimation of atovaquone and proguanil in bulk and tablet dosage form. World journal of Pharmaceutical Research., 6, 338-349 (2017).
Viplava K, Haritha Pavani V. Development and validation of stability-indicating RP-HPLC method for Estimation of Atovaquone. Int. J. Pharm. Clin. Res., 4, 68–72 (2012).
Gurule S, Goswami D, Khuroo AH, Monif T. LC-APCI mass spectrometric method development and validation for the determination of atovaquone in human plasma. Biomed. Chromatogr., 24, 497–505 (2010).
Chambliss AB, Parsons TL, Marzinke MA. An Ultraperformance LC-MS/MS Method for the Quantification of the Antimalarial Atovaquone in Plasma. J. Appl. Lab. Med. An AACC Publ., 1, 400–9 (2017).
How to Cite
Copyright (c) 2020 Sanyam Sharma, Rahul Sharma, Arti Devi, Shammy Jindal, Kamya Goyal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
In submitting an article to Journal of Applied Pharmaceutical Research (JOAPR) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JOAPR are not in breach of any other obligation;
- the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution-NonCommercial 4.0 International License
- I, and all co-authors, agree that, if the article is editorially accepted for publication in Journal of Applied Pharmaceutical Research (JOAPR) data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.